Denis Mollison says:
February 16 2021 at 10:01 am
The 1-dose strategy is indeed a break from precedent, and needs sceptical examination, but so far the evidence is that it’s a good strategy – see recent papers on the two main vaccines used in the UK below.
I don’t see how you can think I am “praising the success of the governments political programme” – most of which I am bitterly opposed to, and I am generaally very critical of their pandemic management: you may well be right in anticipating that their next error will be to ease up lockdown too soon.
But I am also committed to acknowledging facts, including:
– the vaccine delivery programme has been a success by international standards – https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html – for which credit goes at least as much to NHS staff as to government;
– the current evidence is that the 1-dose strategy makes good sense …
Astra-Zeneca – (Lancet, 1 Feb 2021) –
“Interpretation: ChAdOx1 nCoV-19 vaccination programmes aimed at vaccinating a large proportion of the population with a single dose, with a second dose given after a 3 month period is an effective strategy for reducing disease, and may be the optimal for rollout of a pandemic vaccine when supplies are limited in the short term.”
Pfizer – (MedArxiv, 1 Feb 2021) –
” … What our analysis shows is that a single dose of vaccine is highly protective, although it can take up to 21 days to achieve this. The early results coming from Israel support the UK policy of extending the gap between doses by showing that a single dose can give a high level of protection.”
Richard Murphy says:
February 16 2021 at 2:49 pm
I think you and the sycophants writing this stuff will end up with considerable egg on your face
Of course I could be wrong, but every serious epidemiologist seems to be profoundly worried about this programme
“Serious” here meaning “agrees with me”.